Four-Year Biktarvy Data Show High Efficacy, Durable Viral Suppression In Untreated HIV Patients

  • Gilead Sciences Inc GILD announced long-term Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) data showing high efficacy and durable viral suppression in HIV patients.
  • These data were presented at the 11th International AIDS Society (IAS) Conference on HIV Science.
  • A pooled analysis of a 48-week open-label extension of two Phase 3 studies showed that 99% of participants achieved and maintained an undetectable viral load with Biktarvy through four years of follow-up. 
  • Data also included HIV patients aged 65 and older who switched to Biktarvy (n=86) from either Genvoya or a tenofovir disoproxil fumarate (TDF)-based regimen. 
  • The analysis showed that 100% of participants and 74% of participants in the snapshot analysis of the Intention to Treat-Exposed (ITT-E) population maintained high rates of virologic suppression at Week 96 with no virologic failures or emergent resistance.
  • Gilead presented additional Biktarvy data at IAS 2021, including 72-week data from the BRAAVE study showing 99% of Black adults virologically suppressed and switched to Biktarvy from a standard regimen achieved and maintained an undetectable viral load.
  • Price Action: GILD shares closed at $68.63 on Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsHIV
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!